HS3ST2 and ovarian cancer: A subsequent study validated the prognostic significance of HS3ST2 methylation in patients with advanced EOC in three separate dataset of TSGH, AOCS, and TCGA, studies have confirmed that HS3ST2 inhibits the malignant phenotype of ovarian cancer by interfering with various carcinogenic ligand signals, such as IL-6, FGF2 and EGF, and patients with low HS3ST2 expression accompanied by high expression of carcinogenic cytokines or growth factors have the worst prognosis 159.